Back to search

University of British Columbia

Studying the effect of OGX-225, a novel antisense therapy, on prostate cancer cells

Abstract

dc:description

Prostate cancer (PCa) is the most common malignancy diagnosed in Canadian men. If the disease is not detected early the patients would present with metastatic disease. Metastatic PCa represents a challenge for treatment. The primary treatment at this stage is androgen ablation (castration). However, metastatic PCa invariably progress to a castration-resistant form, which does not respond to androgen ablation. This form is a lethal form of the disease, and there are several strategies that have been described to treat this form of cancer. The Insulin-like Growth Factor (IGF) system plays a pivotal role in prostate development and castration-resistant progression. It is tightly regulated by seven high affinity Insulin-like Growth Factor Binding Proteins (IGFBP 1-7). IGFBP-2 and IGFBP-5 are over-expressed in PCa and play a role in castration-resistant progression, while IGFBP-3 is downregulated and inhibits growth of PCa cells. OGX-225 is a novel second- generation antisense drug (ASO) that targets both IGFBP-2 and IGFBP-5. M. Muramaki et al, at the prostate center in Vancouver, showed in their unpublished data that it inhibits the growth PCa cells both in vitro and in vivo, and that it downregulates IGFBP-2 and IGFBP-5. In my thesis, I showed the inability to rescue PCa cells exposed to OGX-225 by adding back IGFBP-5, indicating that the action of OGX-225 is irreversible and targets several targets in addition to IGFBP-2 and IGFBP-5. I also showed the growth inhibitory effect of IGFBP-3 through a mechanism other than apoptosis, while not having an additive effect on PCa cells when combined with OGX-225. This thesis reports the multi-targeting ability of OGX-225 resulting in the inability to rescue PCa cells exposed to it, and gives some insight into the mechanism of action of IGFBP-3 and its effect when combined with OGX-225.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Surgery
Grantor dc:publisher
University of British Columbia
Year dc:date
2010

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Alwaal, Amjad Hassan

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/28647

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Alwaal, Amjad Hassan. Studying the effect of OGX-225, a novel antisense therapy, on prostate cancer cells. master's thesis, University of British Columbia, 2010. http://hdl.handle.net/2429/28647